PT-141 (bremelanotide)
Sexual-desire disorders
Molecular formulaC50H68N14O107 amino acids
What it is
Activates melanocortin receptors; the exact pathway behind its effect on sexual desire is unknown.
Sources [2]
What it is studied for
Bremelanotide has been studied for persistently low sexual desire that causes distress. Vyleesi’s studies assessed changes in desire and related distress in a defined patient group.
Sources [2]
What the evidence says
Human trials for a specific indication
The approval is specific to Vyleesi and its indication; it does not cover every PT-141 formulation. The label excludes general sexual-performance enhancement and lists nausea and temporary blood-pressure increases among important risks.
Sources [2]
Regulatory status
Vyleesi is FDA-approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women who meet its label criteria.
Sources [2]
Sources
- 1FDA (2019): Vyleesi chemistry review and molecular identity FDA chemistry review
- 2Vyleesi prescribing information US prescription label
Source-checked · 26 Oct 2026